Search Results
Your search for ,WHo matches 20700 pages
Showing 14951 - 15000Study Finds No Progression-Free Survival Benefit for Weekly Dose-Dense vs Every-3-Week Paclitaxel Plus Carboplatin in Ovarian Cancer
Weekly dose-dense paclitaxel did not provide a progression-free survival benefit over every-3-week paclitaxel in combination with carboplatin and with or without elective bevacizumab (Avastin) in patients with previously untreated ovarian cancer, according to the results of the phase III GOG-0262...
Light Reflectance Technique May Improve Ability to Remove Prostate Cancer During Surgery
Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery. These findings were reported...
Study Finds 36% Increase in Number of Male Smokers in India Over 17 Years
The number of men smoking tobacco in India rose by more than one third to 108 million between 1998 and 2015, according to a new study published in the journal BMJ Global Health. The study also found that cigarettes were replacing the traditional bidi, a small, inexpensive Indian cigarette,...
Malignant Brain Tumors Most Common Cause of Cancer Deaths in Adolescents and Young Adults
A new report published by Ostrom et al in the journal Neuro-Oncology sponsored by the American Brain Tumor Association (ABTA) found that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39, and the most common cancer occurring...
Improved Outcomes Reported With Adjuvant Therapy in Patients With Early-Stage SCLC Undergoing Complete Resection
Adjuvant chemotherapy and chemotherapy plus prophylactic cranial irradiation were associated with significantly improved survival vs surgery alone in patients with early-stage small cell lung cancer (SCLC) undergoing complete resection, according to an analysis of National Cancer Data Base data...
Steven Shak, MD, on Breast Cancer–Specific Mortality
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
2016 Quality Care Symposium: Study Suggests Many Women With Early Breast Cancer Receive Unnecessary Imaging Tests
A new study suggests that up to 60% of the computed tomography (CT) scans, bone scans, and positron-emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record...
Study Finds No Adverse Impact of Minimally Invasive Hysterectomy on Long-Term Survival in Endometrial Cancer
Use of minimally invasive hysterectomy did not seem to have an adverse impact on long-term survival in women with endometrial cancer, according to an analysis reported in the Journal of Clinical Oncology by Wright et al. Study Details The study involved Surveillance, Epidemiology, and End Result...
Phase III Trial Shows No Benefit of Afatinib vs Trastuzumab Plus Vinorelbine in HER2-Positive Metastatic Breast Cancer
In the phase III LUX-Breast 1 trial reported in The Lancet Oncology, Harbeck et al found no benefit of afatinib (Gilotrif)/vinorelbine vs trastuzumab (Herceptin)/vinorelbine after previous trastuzumab treatment in patients with HER2-positive metastatic breast cancer. Broader inhibition of ErbB...
FDA Approves Everolimus for Neuroendocrine Tumors of Gastrointestinal or Lung Origin
The U.S. Food and Drug Administration today approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced, or metastatic disease. ...
FDA Approves Obinutuzumab in Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) today approved obinutuzumab (Gazyva) for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab...
Cancer Statistics for African Americans, 2016
A new report outlines substantial progress in reducing the mortality gap between blacks and whites for some cancers, while the gap has widened or remained level for two leading cancers: breast cancer in women and colorectal cancer in men. The findings are included in Cancer Statistics for African...
Weight and Height During Adolescence May Impact Future Risk of Developing Non-Hodgkin Lymphoma
A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin lymphoma (NHL). The findings were published by Leiba et al in Cancer. Rates of NHL have increased worldwide, and research suggests that rising rates of obesity may be...
Quality Improvement Projects Aim at Reducing Errors in Prescribing IV and Oral Chemotherapy
Two quality improvement projects described in the Journal of Oncology Practice resulted in reduced errors in prescribing intravenous (IV) and oral chemotherapy. A project at the University of Texas Medical Branch in Galveston outpatient infusion centers first identified 15 different types of...
Increased Cancer Mortality Among Recipients of Solid-Organ Transplants
Solid-organ transplant recipients have a higher rate of cancer mortality than that expected in the general population, according to a Canadian study published in JAMA Oncology. Cancer mortality among transplant recipients “was significantly elevated compared with the Ontario population,” with a...
Eye Movement Affected in Some Former Childhood Cancer Patients
A study from Lund University in Sweden has shown that commonly used chemotherapy toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system. The results were published by Einarsson et al in PLOS One. It was not the former patients' ...
ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer
As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....
Minimal Residual Disease Identified by NPM1 Mutation May Be Prognostic Marker for Poorer Outcome in Standard-Risk AML
In a study reported in The New England Journal of Medicine, Ivey et al found that a leukemia-specific marker consisting of a mutation in the gene encoding nucleophosmin (NPM1) can be used to identify minimal residual disease in peripheral blood in standard-risk acute myeloid leukemia (AML), with...
ASCO Clinical Practice Guideline Update on Ovarian Suppression/Adjuvant Endocrine Therapy in Hormone Receptor–Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Burstein et al, ASCO has released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone receptor–positive breast cancer. The update is based on an update panel...
Chemotherapy Preferable to Radiotherapy to Reduce Distant Pancreatic Cancer Recurrences
Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy. While a course of radiotherapy in addition to chemotherapy and a cancer operation reduced the...
2016 Head and Neck Cancer Symposium: Induction Chemotherapy Does Not Predict Survival Advantage Over Concurrent Chemoradiation
Head and neck cancer patients who receive induction chemotherapy rather than the standard treatment of concurrent chemoradiation do not benefit from increased survival rates and are less likely to receive a full course of radiation, according to research presented by Stokes et al at the 2016...
100% of NCI-Designated Cancer Centers Endorse the Promotion of the HPV Vaccination for Cancer Prevention
All National Cancer Institute (NCI)-designated cancer centers have united to support human papillomavirus (HPV) vaccination (see below). A team of HPV experts drafted a consensus statement that advises widespread use of HPV vaccines to prevent cancer. HPV causes cancer of the cervix, anus, and...
Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes
Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment...
Mistletoe
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Mary-Claire King, PhD, Awarded 2016 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research has announced that Mary-Claire King, PhD, Professor of Genome Sciences and Medicine (Medical Genetics) at the University of Washington, Seattle, has been awarded the 2016 Szent-Györgyi Prize for Progress in Cancer Research. The National Foundation for...
FDA Approves Palbociclib in Combination With Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 19, 2016, the U.S. Food and Drug Administration approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer with...
2016 Head and Neck Cancer Symposium: Chemoradiation May Increase Survival for a Subset of Elderly Head and Neck Cancer Patients
The addition of chemotherapy to radiation therapy improves survival rates among a subset of elderly head and neck cancer patients, specifically those aged 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented by Amini et al at the 2016 Multidisciplinary...
2016 Head and Neck Cancer Symposium: Most Recurrences of HPV-Positive Oropharyngeal Cancer Can Be Found Within 6 Months
For patients treated with definitive radiation therapy for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at 3 months and physical exams during the 6 months following treatment, according to research presented by...
Men Get Breast Cancer Too
Like many men, it never occurred to me that I could get breast cancer. But it turns out it is more common—and deadly—than I thought, with about 2,600 men diagnosed each year with invasive breast cancer and nearly 440 dying of the disease.1 In 2010, I became one of those men, and the diagnosis was...
Oncology Drug Approvals: Year in Review
In 2015, the Office of Hematology and Oncology Products (OHOP) approved 16 new molecular entities. The most notable were drug approvals in disease areas such as non–small cell lung cancer, colorectal cancer, breast cancer, melanoma, renal cancer, and diseases that are particularly difficult to...
Jaclyn Biegel, PhD, Joins Children’s Hospital of Los Angeles as Director of Center for Personalized Medicine
Children’s Hospital Los Angeles (CHLA) has named Jaclyn Biegel, PhD, a leading academic expert on pediatric brain tumors, rhabdoid tumors, and cancer cytogenetics, as the Director of the Center for Personalized Medicine at CHLA. Dr. Biegel, who formerly served as Director of the Cancer Cytogenetics ...
Global Cancer: The Current Reality and the Future Need for Action
The estimated number of cancer cases worldwide in 2008 was 12.7 million, with 7.6 million deaths. By 2030, it is estimated that there will be 22 million newly diagnosed cancer cases and 12 million deaths, shocking to contemplate in dollars and human suffering. Although this impending disaster has...
A Surgeon’s Inspiring Journey to Death
Every so often, a memoir comes along in which the story speaks to universal themes. For that magic to occur, the author must step aside at times and let others tell their story, too. Moreover, the writing must be clear, vibrant, and above all else honest to the core. The recently published memoir...
Emory and Winship Announce Sagar Lonial, MD, as Hematology and Medical Oncology Department Chair
Sagar Lonial, MD, an internationally renowned expert in the biology and treatment of patients with multiple myeloma, has been named Chair of the Department of Hematology and Medical Oncology within Emory University School of Medicine and Winship Cancer Institute. Dr. Lonial assumes this role...
Suresh S. Ramalingam, MD, Named Deputy Director of Winship Cancer Institute
Suresh S. Ramalingam, MD, an internationally recognized lung cancer physician-investigator, has been named Deputy Director of Winship Cancer Institute of Emory University. He will also serve as Assistant Dean for Cancer Research in the Emory School of Medicine. In his role as Winship’s Deputy...
Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and amyloid light-chain (AL) amyloidosis. For other selected abstracts...
ASCO Announces New Award Recognizing Extraordinary Contributions to Cancer Survivorship Care
ASCO has announced the creation of the Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care, intended to recognize and promote the work of pioneers and leaders in the growing field of survivorship. The first award will be presented at the 2017 Cancer Survivorship...
ASCO Official Participates in Vice President’s ‘Moonshot’ Launch
During Vice President Joe Biden’s formal launch of his “moonshot” to cure cancer on January 15, ASCO encouraged a comprehensive approach to accelerate the discovery of new cancer treatments, including issues related to enrollment in clinical trials, access to care, federal funding, and information...
Conquer Cancer Foundation Awards Grants to Drive International Cancer Care Advances
The Conquer Cancer Foundation of ASCO has awarded four 2016 International Innovation Grants to organizations developing projects with the potential to revolutionize cancer control in low- and middle-income countries. This year’s grants will support research in India, Nepal, Uganda, and the...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
Rolapitant Reduces Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately and Highly Emetogenic Chemotherapy
In three phase III studies reported in The Lancet Oncology, the addition of the neurokinin-1 (NK-1) receptor antagonist rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in the prevention of chemotherapy-induced nausea and ...
Evolving Tools for Clinical Decision-Making
Value in cancer care—and how to define it—is a hot topic. There is general agreement that it is some measure of benefit vs cost, but “should the focus be on providing value to patients at a population level or at an individual level?” asked Alan Balch, PhD, CEO of the Patient Advocate Foundation,...
Urologist Steven Brandes, MD, Joins NewYork-Presbyterian/Columbia University Medical Center
Urologist Steven Brandes, MD, has joined NewYork-Presbyterian/Columbia University Medical Center as Chief of Reconstructive Surgery in the Department of Urology, effective February 1. He was also named a Professor of Urology on the faculty of Columbia University College of Physicians and ...
Genomic, Molecular Differences in Tumor Biology May Explain Inferior Survival in African Americans With Kidney Cancer
African Americans who develop metastatic renal cell carcinoma have had worse survival historically than whites. With the advent of targeted therapy, the hope is that the gap in survival would be narrowed. However, a new study has shown that survival for African Americans with metastatic renal cell...
Active Holistic Surveillance May Prevent Unnecessary Biopsies in Low- and Low/Intermediate-Risk Prostate Cancer
The use of prostate-specific antigen (PSA) screening has led to a dramatic rise in the number of men diagnosed with low-grade prostate cancer. Active surveillance is recommended to manage patients with favorable-risk, low-grade prostate cancer, with the goal of avoiding overtreatment of these...
2016 Head and Neck Cancer Symposium: Uninsured and Medicaid Patients More Likely to Present With Advanced Tumors, Experience Cancer-Specific Mortality
Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented by Churilla et al at the 2016...
2016 Head and Neck Cancer Symposium: Cost-Coping Strategies and Perceived Social Isolation in Locally Advanced Head and Neck Cancer
The majority of patients with locally advanced head and neck cancers rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to research presented by Kung et al at the 2016 Multidisciplinary Head and Neck Cancer Symposium (Abstract...
New Technology to Characterize Circulating Tumor Cells Suggests Better Treatment Decision-Making in Prostate Cancer
An early study showed that an experimental blood test (ie, “liquid biopsy”) that characterizes the phenotype and genomic characteristics of circulating tumor cells appears to have utility in personalizing treatment decisions for individual men with advanced prostate cancer.1 The assay—developed and ...
Expert Point of View: Kathryn Schmitz, PhD, MPH
Discussant Kathryn Schmitz, PhD, MPH, Professor of Epidemiology at the Perelman School of Medicine, University of Pennsylvania, lauded the researchers’ successful intervention in what can be a challenging setting. “Dr. Yung presented evidence that it is feasible to conduct an evidence-based,...
Clinic-Based Weight-Loss Intervention Successful in Cancer Survivors
A randomized clinical trial examining the effect of a 15-week healthy living program on weight loss in cancer survivors showed a 5.3% decrease in baseline body weight in those participating in the program.1 “Cancer survivors randomized to a 15-week clinic-based weight-loss intervention lost an...
